Gateways to Clinical Trials: September 2006

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 28, Issue 7, 2006, Pages 451-495

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (3,5 DI TERT BUTYL 4 HYDROXYPHENYL) 1,1 ETHANEBISPHOSPHONIC ACID TETRAISOPROPYL ESTER; 5 (2 BROMOVINYL) 2' DEOXYURIDINE; ADALIMUMAB; ADENOSINE TRIPHOSPHATASE; ALEFACEPT; ALEMTUZUMAB; ANGIOTENSIN DERIVATIVE; ANIDULAFUNGIN; ANTINEOPLASTIC AGENT; ARIPIPRAZOLE; ATOMOXETINE; BENZOYL PEROXIDE; BETAMETHASONE DIPROPIONATE; BEVACIZUMAB; BIPHASIC INSULIN; BORTEZOMIB; BOSENTAN; BOTULINUM TOXIN B; CALCIPOTRIOL; CARDIOVASCULAR AGENT; CASPOFUNGIN; CERTOLIZUMAB PEGOL; CETUXIMAB; CICLESONIDE; CINACALCET; CLINDAMYCIN PHOSPHATE; GASTROINTESTINAL AGENT; HEMATOLOGIC AGENT; IMMUNOLOGIC AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

BLOOD DISEASE; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM DISEASE; ENDOCRINE DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; INFESTATION; KIDNEY DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; RAGWEED; RESPIRATORY TRACT DISEASE; REVIEW; SKIN DISEASE;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY; HUMANS; TREATMENT OUTCOME;

EID: 33750013731     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (251)

1. Brissot, P. et al. Iron chelation therapy with deferasirox (Exjade, ICL670) or deferoxamine results in reduced hepatocellular inflammation and improved liver function in patients with transfusion-dependent anemia. Blood 2005, 106(11): Abst 823.
2. Lundin, J. et al. Treatment of refractory autoimmune hemolytic anemia in B-CLL with alemtuzumab (humanized CD52 MAb). Blood 2005, 106(11): Abst 2967.
3. Vichinsky, E. et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): Comparison between deferasirox (Exjade, ICL670) and deferoxamine (DFO). Blood 2005, 106(11): Abst 2334.
4. Delea, T.E. et al. Once-daily oral deferasirox (Exjade, ICL670) versus infusional deferoxamine as iron chelation therapy in patients with sickle-cell disease receiving frequent transfusions: A cost-effectiveness analysis. Blood 2005, 106(11): Abst 5584.
5. Cappellini, M.D. et al. Patient satisfaction with deferasirox (Exjade, ICL670) an oral form of chelation therapy versus deferoxamine an infused chelation therapy. Blood 2005, 106(11): Abst 2704.
6. Taher, A. et al. Deferasirox (Exjade, ICL670) treatment of inadequately chelated beta-thalassemia patients from the middle east: The ESCALATOR trial. Blood 2005, 106(11): Abst 3840.
7. Wolfram, R.M., Buch, A.N., Xue, Z. et al. Does C-reactive protein predict outcomes of patients with stable angina and acute coronary syndrome who are undergoing percutaneous coronary intervention with drug-eluting stents? J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2801-6.
8. Rha, S.-W., Suh, S.Y., Chwe, U.Y. et al. Is one-month clopidogrel treatment only before major surgery is safe and feasible in patients undergoing percutaneous coronary intervention with drug-eluting stents? Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-31.
9. Lefevre, T., Darremont, O., Morice, M.-C. et al. Preliminary results of the left main TAXUS pilot study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-93.
10. Morrow, D.A., Sabatine, M.S., Wiviott, S.D. et al. Prasugrel suppresses the early rise of sCD40 ligand levels following PCI compared to clopidogrel: A JUMBO-TIMI 26 substudy. Circulation 2005, 112(17, Suppl 2): Abst 2094.
11. Kim, H.-S., Lee, S.-W., Lee, J.-H. et al. Comparison of paclitaxel versus sirolimus-eluting stents for coronary lesions in diabetes: A prospective multicenter randomized, 6-month angiographic follow-up study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-107.
12. Pershukov, I., Batyraliev, T., Pya, Y. et al. Efficacy of treatment of coronary in-stent restenosis using paclitaxel-eluting stent in patients with diabetes mellitus. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-230.
13. Ong, A.T.L. et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005, 96(3): 358.
14. Nakamura, S., Bae, J.-H., Cahyadi, Y.H., Udayachalerm, W., Tresukosol, D., Tansuphaswadikul, S. Long-term follow-up patients with ST-segment elevation acute myocardial infarction treated with sirolimus-eluting stent and paclitaxel-eluting stent. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-95.
15. Holmes, D.R., Jr., Popma, J., Kuntz, R. et al. The SISR trial: 12-month outcomes of sirolimus eluting stents for the treatment of in-stent restenosis. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2922-69.
16. Stone, G.W. et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: The TAXUS V ISR randomized trial. JAMA 2006, 295(11): 1253.
17. Mintz, G., Weissman, N.J., Dawkins, K. et al. Taxus neutralizes the impact of diabetes mellitus on in-stent restenosis: A volumetric intravascular ultrasound meta-analysis from the Taxus IV, V, and VI trials. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2916-68.
18. Daemen, J., Ong, A.T.L., Valgimigli, M. et al. Two-year clinical follow-up of the unrestricted use of the paclitaxel-eluting stent compared to the sirolimus-eluting stent as part of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2912-79.
19. Mintz, G., Weissman, N.J., Dawkins, K. et al. Frequency, predictors, and clinical outcomes of late-acquired incomplete stent apposition in patients treated with Taxus stents: A volumetric intravascular ultrasound meta-analysis from the Taxus IV, V, and VI trials. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2803-3.
20. Colombo, A., Banning, A., Silber, S. et al. TAXUS II 3-year clinical follow-up: Long-term safety and efficacy post polymer-based paclitaxel-eluting stent implantation for de novo coronary artery lesions. Circulation 2005, 112(17, Suppl 2): Abst 3064.
21. Grube, E., Serruys, P.W., Russell, M.E. Four-year clinical results of the Taxus III trial: A feasibility study of the polymer-based, paclitaxel-coated stent for the treatment of in-stent restenosis. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2922-78.
22. Nakamura, S., Bae, J.-H., Cahyadi, Y.H., Udayachalerm, W., Tresukosol, D., Tansuphaswadikul, S. Impact of sirolimus-eluting stents on the outcome of patients with diffuse in-stent restenosis: Multicenter registry in Asia. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-231.
23. Katritsis, D.G., Korovesis, S., Karabinos, I. et al. Sirolimus-versus paclitaxel-eluting stents: A comparison of two consecutive series in routine clinical practice. J Intervent Cardiol 2006, 19(1): 31.
24. Popma, J.J., Kereiakes, D.J., Barb, I. et al. Detailed angiographic and clinical analysis of sidebranch patency following placement of multiple, long (18 mm) overlapped and non-overlapped Cypher stents. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2801-7.
25. Nakamura, S., Bae, J.-H., Cahyadi, Y.H., Udayachalerm, W., Tresukosol, D., Tansuphaswadikul, S. Comparison of efficacy and safety between sirolimus-eluting stent (Cypher) and paclitaxel-eluting stent (Taxus) on the outcome of patients with diffuse in-stent restenosis. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-229.
26. Nakamura, S., Bae, J.-H., Cahyadi, Y.H., Udayachalerm, W., Tresukosol, D., Tansuphaswadikul, S. Impact of sirolimus-eluting stents on the one-year outcome of patients with bifurcation lesions: Multicenter registry in Asia. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-181.
27. Migliorini, A. et al. Predictors of outcome after sirolimus-eluting stent implantation for complex in-stent restenosis. Am J Cardiol 2005, 96(8): 1110.
28. Leon, M.B. Long-term clinical benefit of Cypher sirolimus-eluting coronary stent: Four-year follow-up of the SIRIUS study. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2922-77.
29. Waksman, R., Buch, A.N., Kuchulakanti, P.K. et al. Sirolimus versus paclitaxel eluting stent experience in an unseleced population with coronary artery disease (C-versus T-REWARD registries). J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2912-73.
30. Nakamura, S., Bae, J.-H., Cahyadi, Y.H., Udayachalerm, W., Tresukosol, D., Tansuphaswadikul, S. Comparison of efficacy and safety between sirolimus-eluting stent (Cypher) and paclitaxel-eluting stent (Taxus) on the outcome of patients with chronic total occlusions: Multicenter registry in Asia. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-78.
31. Sakurai, R., Hongo, Y., Honda, Y. et al. A randomized comparison of ABT-578 eluting phosphorylcholine-coated cobalt-chromium stents with bare metal stents in de novo coronary lesions: Final intravascular ultrasound results from the ENDEAVOR II trial. Circulation 2005, 112(17, Suppl 2): Abst 3206.
32. Grube, E., Zoccai, G.B., Sangiorgi, G. et al. Assessing the safety and effectiveness of Taxus in 183 patients with chronic total occlusions: Insights from the TRUE study. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-77.
33. Aoki, J. et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 2005, 46(9): 1670.
34. Morice, M.C., Serruys, P.W., Colombo, A. et al. Prospective randomized multi-center head to head comparison of the sirolimus-eluting stent (Cypher) and the paclitaxel-eluting stent (Taxus): Twelve-month outcome of the REALITY trial. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-108.
35. White, H.D., Banas, J., Parkhomenko, A., Patni, R., Mukherjee, R., Zannad, F. Favorable outcomes with 25 mg of eplerenone in patients with post-AMI heart failure: Results from the EPHESUS trial. Circulation 2005, 112(17, Suppl 2): Abst 3026.
36. Lipsic, E., Van der Meer, P., Voors, A.A. et al. A single bolus of long-acting erythropoietin analogue darbepoetin in patients with an acute myocardial infarction: A randomized feasibility and safety study. Circulation 2005, 112(17, Suppl 2): Abst 2055.
37. Tsujita, K., Shimomura, H., Nakamura, Y. et al. Long-term efficacy of edaravone in patients with acute myocardial infarction. Circulation 2005, 112(17, Suppl 2): Abst 2054.
38. Yusuf, S. et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction. JAMA 2006, 295(13): 1519.
39. Schulman, S.P., Becker, L.C., Kass, D.A. et al. L-arginine therapy in acute myocardial infarction: The vascular interaction with age in myocardial infarction (VINTAGE MI) randomized clinical trial. JAMA 2006, 295(1): 58.
40. Biondi-Zoccai, G., Sangiorgi, G., Agostoni, P. et al. Safety and effectiveness of paclitaxel-eluting stent implantation in over 1000 very high-risk patients: Insights from the prospective multicenter Taxus in Real-life Usage Evaluation (TRUE) study. J Am Coll Cardiol 2006, 47(4, Suppl 2): Abst 2922-80.
41. Gade, C.L.F., Feldman, D.N., Slotwiner, A.J. et al. Safety of sirolimus-eluting stents in patients with ST segment elevation myocardial infarctions and thrombus-laden lesions. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-145.
42. Safety and efficacy of extended exposure to several doses of a new oral direct thrombin inhibitor dabigatran etexilate in atrial fibrillation. Cerebrovasc Dis 2006, 21(Suppl 4): 2.
43. Taylor, A.L. The African American heart failure trial: A clinical trial update. Am J Cardiol 2005, 96(7, Suppl 2): 44.
44. Udelson, J.E., McGrew, F., Flores, E. et al. Effects of the vasopressin V2 receptor antagonist, tolvaptan, on the long-term progression of left ventricular dilatation in patients with heart failure. Circulation 2005, 112(17, Suppl 2): Abst 2415.
45. Poldermans, D., Gamboa, R., Fomina, I. et al. Comparative safety and blood pressure (BP)-lowering efficacy of a combination of amlodipine (Amlo)+valsartan and lisinopril+hydrochlorothiazide (HCT) in patients with stage 2 hypertension. J Clin Hypertens 2006, 8(5, Suppl A): Abst P-217.
46. Ratner, P.H., Wingertzahn, M.A., Hall, N., Darken, P., Shah, T. Effects of coadministration of intranasal ciclesonide (CIC) and inhaled beclomethasone dipropionate (BDP) on cortisol suppression. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1003.
47. Antoniazzi, F. et al. Early bisphosphonate treatment in infants with severe osteogenesis imperfecta (OI). Horm Res 2005, 64 (Suppl 1): Abst P1-278.
48. Kirby, R. Cinacalcet for secondary hyperparathyroidism in ESRD patients. Nat Clin Pract Nephrol 2006, 2(1): 8.
49. Johanson, J.F. et al. Long-term efficacy of lubiprostone for the treatment of chronic constipation. Gastroenterology 2006, 130(4, Suppl 2): Abst M1171.
50. Ueno, R. et al. Long-term safety and efficacy of lubiprostone for the treatment of chronic constipation in elderly subjects. Gastroenterology 2006, 130(4, Suppl 2): Abst S1260.
51. Ueno, R. et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in elderly vs. non-elderly subjects. Gastroenterology 2006, 130(4, Suppl 2): Abst S1262.
52. Ueno, R. et al. Efficacy and safety of lubiprostone for the treatment of chronic constipation in male vs female subjects. Gastroenterology 2006, 130(4, Suppl 2): Abst M1195.
53. Chey, W.D. et al. Tegaserod is superior to placebo in normalizing stool consistency and in increasing frequency of complete spontaneous bowel movements (CSBMs) in chronic constipation (CC) patients who present with hard stools. Am J Gastroenterol 2005, 100(9, Suppl): Abst 929.
54. Shetzline, M. et al. Patients with chronic constipation who respond to tegaserod after 4 weeks maintain symptom improvement for over 13 months. Am J Gastroenterol 2005, 100(9, Suppl): Abst 927.
55. Schreiber, S., Lawrance, I.C., McColm, J.A., Bloomfield, R., Snadborn, W.J. How effective is anti-TNF-alpha therapy? A re-analysis of the PRECISE 2 maintenance trial of monthly subcutaneous certolizumab pegol in active Crohn's disease using remission to redefine all efficacy measures. Gastroenterology 2006, 130(4, Suppl 2): Abst T1140.
56. Ai, M., Yamaguchi, T., Odaka, T. et al. Objective assessment of the antispasmodic effect of shakuyaku-kanzo-to (TJ-68), a Chinese herbal medicine, on the colonic wall by direct spraying during colonoscopy. World J Gastroenterol 2006, 12(5): 760.
57. Foroughi, S., Mannon, P.J., Bernardino, L.B. et al. Pilot study of omalizumab (anti-IgE) in eosinophilic gastroenteritis. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1174.
58. Khoshoo, V., Armstead, C., Landry, L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment Pharmacol Ther 2006, 23(1): 191.
59. Johanson, J.F. et al. A dose-ranging, double-blind, placebo-controlled study of lubiprostone in subjects with irritable bowel syndrome and constipation (c-IBS). Gastroenterology 2006, 130(4, Suppl 2): Abst 131.
60. Hasan, M., Hoque, S.T., Haq, N.K. Tegaserod: Patient satisfaction and tolerability in Bangladeshi patients. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst TP131.
61. Kim, J.P., Yoo, K.-S., Jung, J.O. et al. The effect of tegaserod on volume of colonoscopy lavage solution: Randomized controlled colonoscopy preparation trial comparing tegaserod plus 2-liter of PEG-electrolyte solution (PEG-ELS) versus standard 4-liter PEG-ELS or oral sodium phosphate. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst MP143.
62. Angelucci, E. et al. Iron chelation therapy with deferasirox (Exjade, ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood 2005, 106(11): Abst 2696.
63. Lim, S.G., Ng, T.M., Kung, N. et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006, 166(1): 49.
64. Chang, T.-T., Han, K.-H., Yoon, S.-K. et al. Entecavir (ETV) demonstrates consistent responses throughout baseline demographic subgroups for the treatment of nucleoside-naive, HBeAg (positive) and HBeAg (negative) patients with chronic hepatitis B. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst TO048.
65. Sollano, J., Chang, T.-T., Han, K.-H. et al. Entecavir is well tolerated for the treatment of nucleoside-naive and lamivudine-refractory chronic hepatitis B: Phase 213 safety results. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst WP047.
66. Yao, G., Chen, C., Lu, W. et al. Entecavir is superior to lamivudine for the treatment of chronic hepatitis B: Results of the phase 3 study ETV-023 in nucleoside-naive patients. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst WP050.
67. Han, K.-H., Yoon, S.-K., Cho, S.-W. et al. Sustained response off-treatment to entecavir and lamivudine after 48 weeks of treatment in nucleoside-naive, HBeAg (positive) patients: 24-week follow-up results of phase 3 study-022. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst WP044.
68. Yao, G., Zhou, X., Xu, D. et al. A randomized, placebo-controlled study (ETV-056) in China of the efficacy and safety of entecavir (ETV) in chronic hepatitis B (CHB) patients who have failed lamivudine (LVD) therapy. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst TO047.
69. Zhou, X.J., Lim, S.G., Lloyd, D.M., Chao, G.C., Brown, N.A., Lai, C.L. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: Pharmacodynamic implications. Antimicrob Agents Chemother 2006, 50(3): 874.
70. Lee, H.W., Kim, J.-H., Han, K.-H. et al. A single center experience of interferon alpha-2a plus ribavirin for the treatment of 200 Korean patients with chronic hepatitis C: Peginterferon alpha-2a compared with interferon alpha. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst WP067.
71. Tran, T.T., Patel, Y., Benner, J.S., Petrilla, A.A., Poordad, F. Neutropenia associated with pegylated interferon treatment for chronic hepatitis C: A single center experience. Am J Gastroenterol 2005, 100(9, Suppl): Abst 315.
72. Lee, H., Paik, S.W., Choi, M.S. et al. PEG-interferon alfa-2a plus ribavirin for initital treatment of chronic hepatitis C in Korea. J Gastroenterol Hepatol 2005, 20(Suppl 2): Abst TO054.
73. Aberer, W. Desloratadine for the relief of nasal and non-nasal allergic symptoms: An observational study. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1237.
74. Simons, K.J., Simons, F.E.R., Strolin-Benedetti, M., Gillard, M., Baltes, E. Levocetirizine: H1-receptor occupancy in allergic children aged 6-11 years. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 471.
75. Banerji, A., Long, A.A. Decrease in skin test wheat and flare response after omalizumab therapy. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1209.
76. Klunker, S., Francis, J.N., Casale, T.B., Durham, S.R. Anti-IgE therapy inhibits IgE-facilitated allergen presentation and increases the efficacy of ragweed immunotherapy. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 347.
77. Busse, W., Fox, H., Surrey, K., Maykut, R., Reisner, C. Clinically relevant improvements in asthma-related quality of life in patients receiving omalizumab as add-on therapy. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 30.
78. Berger, W., Fox, H., Ayre, G., Blogg, M., Massanari, M., Reisner, C. Add-on omalizumab improves asthma control across multiple measures of response in patients with severe persistent allergic asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 32.
79. Hebert, J., Rolli, M., Gao, J., Reisner, C. Omalizumab, an anti-IgE monoclonal antibody, demonstrates long-term asthma control, safety and tolerability in patients with severe allergic asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 35.
80. Cooper, P.J., Lima, F., Sarinho, E.C. et al. Safety of anti-IgE therapy with omalizumab in allergic patients at risk of geohelminth infection. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 33.
81. Paller, A.S., Lebwohl, M., Fleischer, A.B., Jr. et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J Am Acad Dermatol 2005, 52(5): 810.
82. Passalacqua, G., Pasquali, M., Rogkakou, A. et al. Effects of levocetirizine on symptoms and quality of life in persistent allergic rhinitis and comorbid asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1233.
83. Loureiro, C., Chieira, C., Guilherme, M.A.P. et al. Desloratadine is effective in relieving the nasal and non-nasal symptoms of perennial allergic rhinitis (PAR) in patients with or without concurrent respiratory tract conditions. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1238.
84. Montagne, M., Gennaro, C., Bouchard, M., Flores, D., Hernandez, G., Urdaneta, E. Desloratadine is safe and effective in the treatment of the nasal symptoms of perennial allergic rhinitis (PAR): Results of two observational studies. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1236.
85. Ciebiada, M., Gorska-Ciebiada, M., DuBuske, L.M., Gorski, P. Combination therapy with montelukast and anti-histamines (desloratadine or levocetirizine) improves quality of life in patients with persistent allergic rhinitis: A double blind placebo controlled study. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 642.
86. Repp, R. et al. Low dose alemtuzumab is effective in the treatment of severe steroid-refractory acute graft-versus-host disease. Bone Marrow Transplant 2006, 37(Suppl 1): Abst P481.
87. Rabkin, J.G., McElhiney, M.C., Rabkin, R., McGrath, P.J., Ferrando, S.J. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. Am J Psychiatry 2006, 163(1): 59.
88. Said, T., Nampoory, M.R., Nair, M.P. et al. Safety of caspofungin for treating invasive nasal sinus aspergillosis in a kidney transplant recipient. Transplant Proc 2005, 37(7): 3038.
89. Menendez, R. Omalizumab induces resolution of fungal sinusitis in a 15 year old asthmatic patient. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 31.
90. McPherson, E. et al. Deficiency of 2,3-dimethoxy-5-methyl-6-decaprenyl-1, 4-benzoquinone (Mitoquinone) and hyperlactic acidosis in human immunodeficiency virus (HIV) patients with head and neck squamous cell carcinoma (HNSCC) treated with nucleoside reverse transcriptase inhibitor (NRTI)-based HAART and chemoradiation. Blood 2005, 106(11): Abst 3899.
91. Bzowej, N. et al. Phase III comparison of telbivudine vs. lamivudine in patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year. Gastroenterology 2006, 130(4, Suppl 2): Abst 482.
92. Poordad, F., Tran, T.T., Patel, Y., Ayoub, W., Newland, K. Use of erythropoietin increases the likelihood of achieving viral clearance in HCV infected patients treated with pegylated interferon and ribavirin. Am J Gastroenterol 2005, 100(9, Suppl): Abst 327.
93. Mukherjee, S. Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2005, 37(10): 4403.
94. Gul, U., Gonul, M., Cakmak, S.K., Gunduz, H. Evaluation of the efficacy of oral brivudin therapy in herpes zoster patients. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P08.34.
95. Rodriguez, A., Hill-Zabala, C., Sloan, L. et al. Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen. J Acquir Immune Defic Syndr (JAIDS) 2006, 41(1): 127.
96. Keller, M.J., Zerhouni-Layachi, B., Cheshenko, N. et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: A double-blind placebo-controlled trial. J Infect Dis 2006, 193(1): 27.
97. Nadel, S., Williams, M.D., Wang, D., Yan, S.C., Planquois, J.-M., Giroir, B. Changes in markers of coagulation and inflammation in patients with pediatric severe sepsis treated with drotrecogin alfa (activated). Crit Care Med 2005, 33(12, Suppl): Abst 169-T.
98. Goldstein, B., Williams, M., Wang, D., Angle, R., Giroir, B. The safety of drotrecogin alfa (activated) in pediatric patients with severe sepsis. Crit Care Med 2005, 33(12, Suppl): Abst 168-T.
99. Grochowiecki, T., Nazarewski, S., Meszaros, J. et al. Use of drotrecogin alpha (recombinant human activated protein C, rhAPC) in the treatment of severe sepsis induced by graft pancreatitis after simultaneous pancreas and kidney transplantation: A case report. Transplant Proc 2006, 38(1): 276.
100. Thomas, J.J., Octaviani-Agostini, R., Steingrub, J.S., Tidswell, M., Higgins, T.L. Acute hemodynamic changes during drotrecogin alfa (activated) (DTAA) infusion in septic shock. Crit Care Med 2005, 33(12, Suppl): Abst 36.
101. Abdelhady, H., Johnson, S.B., Adams, R., Haddad, M., Pierson, R., Griffith, B.P. Drotrecogin alfa (APC) in a patient requiring biventricular assist device (BiVAD) support. Crit Care Med 2005, 33(12, Suppl): Abst 277-M.
102. Simoes, J.A., Bahamondes, L.G., Camargo, R.P. et al. A pilot clinical trial comparing an acid-buffering formulation (ACID-FORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis. Br J Clin Pharmacol 2006, 61(2): 211.
103. Schiaffini, R. et al. A long term observational study comparing the efficacy of continuous subcutaneous insulin infusion (CSII) to multiple daily injections (MDI) with glargine as basal insulin in type 1 age matched diabetic children. Horm Res 2005, 64(Suppl 1): Abst OR1-63.
104. Heine, R.J. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. A randomized trial. Ann Intern Med 2005, 143(8): 559.
105. Zelenina, T.A. et al. Estrogen replacement therapy improves endothelial function in postmenopausal women with diabetes. Climacteric 2005, 8(Suppl 2): Abst 0340.
106. Gupta, M.S., Singhal, M., Shanker, V., Yadav, R.K., Kaushal, A. Ezetimibe as an adjunct to atorvastatin in patients of dyslipidemia. Indian Heart J 2005, 57(5): Abst 469.
107. Stein, E.A., Ose, L., Retterstol, K. et al. Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. Circulation 2005, 112(17, Suppl 2): Abst 3788.
108. Pearson, T.A. et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: The ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005, 80(5): 587.
109. Khalil, O., Winiarska, M., Agloria, M. et al. Rosuvastatin acceptability, efficacy, and safety in hypercholesterolemic patients unable to tolerate other statins. J Invest Med 2006, 54(Suppl 2): Abst 41.
110. Efrati, S., Averbuch, M., Dishy, V. et al. The effect of simvastatin, ezetimibe and their combination on lipids profile, arterial stiffness and inflammatory markers. Clin Pharmacol Ther 2006, 79(2): Abst OI-A-2.
111. Stalenhoef, A.F.H. et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: Results of the COMETS study. Eur Heart J 2005, 26(24): 2664.
112. Porter, J. et al. Iron chelation efficiency of deferasirox (Exjade, ICL670) in patients with transfusional hemosiderosis. Blood 2005, 106(11): Abst 2690.
113. Henrickson, M. Sustained efficacy of anakinra in refractory systemic arthritis failing etanercept. Arthritis Rheum 2005, 52(9, Suppl): Abst 131.
114. Choy, E.H.S., Burmester, G.R., Bombardieri, S., Van den Bosch, F., Sasso, E.H., Weinberg, M.A. Efficacy of adalimumab in psoriatic arthritis as measured by the disease activity score 28. Arthritis Rheum 2005, 52(9, Suppl): Abst 497.
115. Van Vollenhoven, R., Breedveld, F.C., Kavanaugh, A.F., Cohen, S.B., Perez, J.L., Spencer-Green, G.T. The clinical and radiographic efficacy of every-other-week vs. weekly dosing frequency of adalimumab (Humira) in the treatment of early rheumatoid arthritis (RA). Arthritis Rheum 2005, 52(9, Suppl): Abst 271.
116. Weisman, M.H., Strand, V., Cifaldi, M.A., Sterz, R. Adalimumab (Humira) plus methotrexate is superior to MTX alone in improving physical function, as measured by the SF-36, in patients with early rheumatoid arthritis. Arthritis Rheum 2005, 52(9, Suppl): Abst 1018.
117. Garnero, P., Charni, N., Voorzanger-Rousselot, N., Radin, A., Bingham, C.O. Effects of IL-1 trap on biochemical markers of inflammation and joint tissue breakdown in patients with rheumatoid arthritis. Arthritis Rheum 2005, 52(9, Suppl): Abst 868.
118. Genant, H.K., Prevrhal, S., Crans, G.G., Glass, E.V., Krege, J.H. Teriparatide reduces vertebral height loss in women with osteoporosis and severe prevalent vertebral fractures. J Bone Miner Res 2005, 20(Suppl 1): Abst M404.
119. Black, D.M., Rosen, C.J., Palermo, L. et al. The effect of 1 year of alendronate following 1 year of PTH 1-84: Second year results from the PTH and alendronate (PATH) trial. Bone 2005, 36(Suppl 2): Abst P687-Tu.
120. Rat, A.-C., Loeuille, D., Chary-Valckenaere, I. et al. Responsiveness of the OAKHQOL after total knee and hip replacement surgery and after hyaluronic acid injections. Arthritis Rheum 2005, 52(9, Suppl): Abst 1787.
121. Dougados, M., Moore, A., Gitton, X., Sloan, V.S. Evaluation of the clinical relevance of the symptomatic efficacy of lumiracoxib in osteoarthritis utilising the patient acceptable symptom state (PASS) concept. Osteoarthr Cartilage 2005, 13(Suppl A): Abst P130.
122. Allanore, Y., Meune, C., Vignaux, O. et al. Beneficial effects of bosentan on myocardial perfusion and function assessed by cardiac magnetic resonance imaging and tissue Doppler imaging in systemic sclerosis. Arthritis Rheum 2005, 52(9, Suppl): Abst 376.
123. Van der Heijde, D., Luo, M., Matsumoto, A. et al. Adalimumab improves health-related quality of life in patients with active ankylosing spondylitis-The ATLAS trial. Arthritis Rheum 2005, 52(9, Suppl): Abst 490.
124. Reddy, N.J., Beelen, A.P., Perez, R.P. et al. An intrapatient dose escalation and tolerability study of adenosine triphosphate infusions on a weekly schedule for eight weeks in patients with advanced solid tumors. Clin Pharmacol Ther 2006, 79(2): Abst PI-16.
125. du Bois, A., Jung, B., Loehr, a., Schaller-Kranz, T., Cohen, M., Frickhofen, N. A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. Br J Cancer 2006, 94(1): 79.
126. Bonner, J.A., Harari, P.M., Giralt, J. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6): 567.
127. Hande, K.R., Hagey, A., Berlin, J. et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: Results of a phase I study. Clin Cancer Res 2006, 12(9): 2834.
128. Tolcher, A.W., Wakelee, H., Mita, M. et al. A phase I clinical study of HGS-ETR2, a fully-human monoclonal antibody to TRAIL-R2 in patients with advanced solid tumors. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 543.
129. Siu, L.L., Awada, A., Takimoto, C.H. et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006, 12(1): 144.
130. Sessa, C., Vigano, L., Grasselli, G. et al. Phase I clinical and pharmacological evaluation of the multi-tyrosine kinase inhibitor SU006668 by chronic oral dosing. Eur J Cancer 2006, 42(2): 171.
131. Levine, A.M., Tulpule, A., Quinn, D.I. et al. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: Decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol 2006, 24(11): 1712.
132. Lamm, D., Stephenson, J., Tsai, H. et al. A phase 1 dose-escalation trial of intravesical CG0070 for superficial transitional cell carcinoma (TCC) of the bladder after bacillus Calmette-Guerin (BCG) failure. J Urol 2006, 175(4, Suppl): Abst 844.
133. Reardon, D.A., Akabani, G., Coleman, R.E. et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J Clin Oncol 2006, 24(1): 115.
134. Vogelbaum, M., Peereboom, D., Stevens, G., Barnett, G., Brewer, C. Phase II study of erlotinib single agent therapy in recurrent glioblastoma multiforme. Eur J Cancer - Suppl 2005, 3(2): Abst 486.
135. Nakagawa, H., Tamura, M., Fukushima, Y., Majima, S., Yoshioka, K., Itoh, K. Clinical trial of continuous intrathecal or intracavitary infusion of sodium butyrate for leptomeningeal carcinomatosis or recurrent malignant glioma. Proc Am Assoc Cancer Res (AACR) 2005, 46: Abst 5764.
136. Rodgers, K.E., Oliver, J., Dizerega, G.S. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol 2006, 57(5): 559.
137. Hawle, H., Thuerlimann, B., Pagani, O. et al. Fulvestrant in heavily pretreated patients with advanced breast cancer: Experience from a Named Patient Programme in Switzerland. Eur J Cancer - Suppl 2005, 3(2): Abst 445.
138. Steger, G., Bartsch, R., Wenzel, C. et al. Results from a pilot study of
139. Baselga, J. et al. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J Clin Oncol 2005, 23(23): 5323.
140. Catania, C., Ascione, G., Medici, M. et al. Evaluation of fulvestrant (F) activity and toxicity in heavily pretreated patients with advanced breast cancer (ABC). Eur J Cancer - Suppl 2005, 3(2): Abst 450.
141. Smith, H.O., Jiang, C.S., Weiss, G.R. et al. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: A Southwest Oncology Group study. Int J Gynecol Cancer 2006, 16(1): 298.
142. Berkenblit, A., Matulonis, U.A., Kroener, J.F. et al. A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. Gynecol Oncol 2005, 99(1): 50.
143. Kretzschmar, A., Berry, S., Cunningham, D. et al. Starting bevacizumab shortly after venous access device implantation appears not to increase wound healing/bleeding complications nor catheter related thromboses-Preliminary results from first BEAT. Eur J Cancer - Suppl 2005, 3(2): Abst 629.
144. Peeters, M., Raoul, J.-L., Van Laethem, J.-L. et al. Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC). Eur J Cancer - Suppl 2005, 3(2): Abst 664.
145. Niederle, N., Freier, P., Porschen, R. et al. Erlotinib as single agent in 2nd and 3rd line treatment in patients with metastatic colorectal cancer: Results of a two-cohort multicenter phase II trial. Eur J Cancer - Suppl 2005, 3(2): Abst 649.
146. Trarbach, T., Schleucher, N., Junker, U. et al. Phase I/II study of PTK/ZK, a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Eur J Cancer - Suppl 2005, 3(2): Abst 639.
147. Stroehlein, M., Lordick, F., Ruettinger, D. et al. Intraperitoneal application of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) for the treatment of peritoneal carcinomatosis due to GI cancer: Results of a phase I trial. Eur J Cancer - Suppl 2005, 3(2): Abst 659.
148. Larre, S., Schoepen, Y., De La Taille, A. et al. Bevacizumab treatment for multi-metastatic renal cancer: Results after 6 months. Eur Urol Suppl 2006, 5(2): Abst 1059.
149. Dowlati, A., Chapman, R., Subbiah, S. et al. Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer. Invest New Drugs 2005, 23(6): 563.
150. Butts, C. et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005, 23(27): 6674.
151. Stinchcombe, T.E., Buzkova, P., Choksi, J. et al. A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. Lung Cancer 2006, 52(3): 305.
152. Johnson, F.M. et al. Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer 2006, 106(2): 366.
153. Antonia, S.J., Mirza, N., Fricke, I. et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006, 12(3): 878.
154. Ernst, D.S., Eisenhauer, E., Wainman, N. et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs 2005, 23(6): 569.
155. Hank, J.A., Choi, B., Sondel, P.M. et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother 2006, 55(7): 761.
156. Eilender, D., Lorusso, P., Thomas, L. et al. 4,4′- Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007): A topical treatment for cutaneous metastases from malignant cancers. Cancer Chemother Pharmacol 2006, 57(6): 719.
157. Lewis, K.D., Thompson, J.A., Weber, J.S. et al. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs 2006, 24(1): 89.
158. D'Agostino, G., del Campo, J., Mellado, B. et al. A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006, 16(1): 71.
159. Macdonald, J.S. et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) study. Invest New Drugs 2005, 23(5): 485.
160. Gralla, R., Symanowski, J., Boyer, M. et al. Evaluating improvement in patient-reported dyspnea and pulmonary function tests (PFTs) in patients with malignant pleural mesothelioma (MPM): An analysis as part of the 448-patient randomized pemetrexed plus cisplatin versus cisplatin trial. Lung Cancer 2005, 49(Suppl 2): Abst P-401.
161. Ceresoli, G.L., Zucali, P.A., Favaretto, A.G. et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006, 24(9): 1443.
162. Ceresoli, G., Zucali, P., Van Hemert, R. et al. Positron emission tomography with F18-fluorodeoxyglucose (FDG-PET) in malignant pleural mesothelioma (MPM): Prediction of response to chemotherapy by quantitative assessment of standard uptake value (SUV). Lung Cancer 2005, 49(Suppl 2): Abst P-394.
163. Fiedler, W., Tchen, N., Bloch, J. et al. A study from the EORTC new drug development group: Open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. Eur J Cancer 2006, 42(2): 200.
164. Maclean, C., Ulys, A., Jankevicius, F., Kaniusas, D., Drewe, J., Larsen, F. Efficacy and safety of teverelix, a new gonadotrophin releasing hormone antagonist in patients with advanced prostate cancer. Results from a phase 2 multicentre, open-label, pilot study investigating an initial intramuscular loading dose regimen of teverelix. Eur Urol Suppl 2006, 5(2): Abst 916.
165. Machiels, J., Coche, J., Scalliet, P. et al. Phase I/II study of preoperative cetuximab, capecitabine and external beam radiotherapy in patients with locally advanced rectal cancer (LARC). Eur J Cancer - Suppl 2005, 3(2): Abst 646.
166. Greiner, J. et al. RHAMM/CD168-R3 peptide vaccination of HLA-A2+ patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM). Blood 2005, 106(11): Abst 2781.
167. Potenza, L. et al. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission. Haematologica 2005, 90(9): 1275.
168. Hummel, M. et al. Successful treatment of tumor lysis syndrome (TLS) with low doses of rasburicase in patients with impaired renal function (IRF). Blood 2005, 106(11): Abst 3332.
169. Thieblemont, C. et al. Maintenance alemtuzumab in refractory B-cell chronic lymphocytic leukemia patients: Updated data. Blood 2005, 106(11): Abst 5032.
170. Gribben, J. et al. Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: Results from a phase II study. Blood 2005, 106(11): Abst 5046.
171. Fiegl, M. et al. Alemtuzumab is effective in patients with advanced, pretreated B-cell chronic lymphocytic leukemia: A nationwide study of routine use in Austria. Blood 2005, 106(11): Abst 2971.
172. Younes, A. et al. A pilot study of yttrium 90(90Y) ibritumomab tiuxetan (Zevalin) in patients with relapsed and refractory classical Hodgkin lymphoma (HL): Delivering cross fire radiation by targeting reactive B cells in the microenvironment. Blood 2005, 106(11): Abst 4791.
173. Forero-Torres, A. et al. A preliminary report of a phase I study of zevalin using a modified treatment regimen for relapsed or refractory CD20+ B-cell follicular or transformed non-Hodgkin's lymphoma (NHL). Blood 2005, 106(11): Abst 4798.
174. Jagannath, S. et al. Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Blood 2005, 106(11): Abst 783.
175. Drach, J. et al. Short survival, despite promising response rates, after bortezomib treatment of multiple myeloma patients with a 13q-deletion. Blood 2005, 106(11): Abst 509.
176. Wang, M. et al. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005, 106(11): Abst 784.
177. Treon, S. et al. Phase II study of bortezomib in Waldenstrom's macroglobulinemia: Results of WMCTG Trial 03-248. Blood 2005, 106(11): Abst 490.
178. Chanan-Khan, A.A. et al. Safety and efficacy of bortezomib in multiple myeloma patients with renal failure requiring dialysis. Blood 2005, 106(11): Abst 2550.
179. Kantarjian, H., Issa, J.-P.J., Rosenfeld, C.S. et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Results of a phase III randomized study. Cancer 2006, 106(8): 1794.
180. Goss, T.F., Szende, A., Brueckner, J. et al. Cost-effectiveness of lenalidomide in the treatment of patients with transfusion-dependent myelodysplastic syndromes (MDS) in the United States. Blood 2005, 106(11): Abst 1338.
181. Kurzock, R., Verstovsek, S., Wright, J.J. et al. Alternate week administration of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in patients with myelodysplastic syndrome: Results of a phase 1 study. Blood 2005, 106(11): Abst 2521.
182. Barragan, E., Hernandez, J. Efficacy of atomoxetine treatment in children with ADHD and epilepsy. J Neurol Sci 2005, 238 (Suppl 1): Abst 0056.
183. Corrigan, M. et al. Adjunctive eszopiclone and fluoxetine in major depressive disorder and insomnia: Effects on sleep and depression. Neuropsychopharmacology 2005, 30(Suppl 1): S104.
184. Dore, M.P., Maragkoudakis, E., Pironti, A. et al. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter 2006, 11(1): 52.
185. Lew, M.F., Factor, S. A 4 year observational study of repeated dosing with botulinum toxin type B in patients with cervical dystonia. Neurology 2006, 66(5, Suppl 2): Abst P05.126.
186. Lesser, R.P. et al. Efficacy and safety of rufinamide monotherapy for the treatment of patients with refractory partial seizures. Epilepsia 2005, 46(Suppl 8): Abst 2.258.
187. Glauser, T. et al. Efficacy and safety of rufinamide as adjunctive therapy for inadequately controlled partial seizures in pediatric patients. Epilepsia 2005, 46(Suppl 8): Abst 2.309.
188. Ouellet, D., Miller, R., Chappell, P.B., Farber, R., Corrigan, B.W. Dose-response analysis of the effect of indiplon on subjective wake after sleep onset. Clin Pharmacol Ther 2006, 79(2): Abst PI-40.
189. Corrigan, B.W., Miller, R., Chappell, P.B., Farber, R., Ouellet, D. Dose-response for the effect of indiplon on sleep time duration. Clin Pharmacol Ther 2006, 79(2): Abst PI-39.
190. Gold, R., Havrdova, E., Kappos, L. et al. Safety of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: Results of a phase 2 study. J Neurol 2006, 253(Suppl 2): Abst P573.
191. Kappos, L., Miller, D.H., MacManus, D.G. et al. Efficacy of a novel oral single-agent fumarate, BG00012, in patients with relapsing-remitting multiple sclerosis: Results of a phase 2 study. J Neurol 2006, 253(Suppl 2): Abst O108.
192. Confavreux, C., Stuart, W.H., Calabresi, P.A. et al. Subgroup analyses from SENTINEL: A randomized controlled trial of natalizumab (Tysabri) and interferon beta-1a (Aonex) in relapsing multiple sclerosis (MS). J Neurol Sci 2005, 238(Suppl 1): Abst OPL102.
193. Radue, E.-W., Stuart, W.H., Calabresi, P.A. et al. SENTINEL: A randomized controlled trial of natalizumab (Tysabri) and interferon beta-1a (Avnoex) in relapsing multiple sclerosis (MS): Magnetic resonance imaging (MRI) results. J Neurol Sci 2005, 238(Suppl 1): Abst OPL101.
194. Panitch, H.S., Thisted, R.A., Smith, R.A. et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006, 59(5): 780.
195. Zeiler, B., Jost, W. Stalevo is efficient and well-tolerated in patients with Parkinson's disease experiencing wearing-off symptoms. Mov Disord 2006, 21(Suppl 13): Abst P207.
196. Bo, W. et al. A randomized controlled trial of ligustrazine for acute ischemic stroke. J Neurol Sci 2005, 238(Suppl 1): Abst 1237.
197. Giuliano, F., Sanchez Ramos, A., Ernst, D.L., Del Popolo, G., Zhao, Y., Casariego, J. Tadalafil in men with erectile dysfunction and spinal cord injury. Eur Urol Suppl 2006, 5(2): Abst 627.
198. Maas, A.I., Murray, G., Henney, H., III. et al. Efficacy and safety of dexanabinol in severe traumatic brain injury: Results of a phase III randomised, placebo-controlled, clinical trial. Lancet Neurol 2006, 5(1): 38.
199. Reimherr, F.W., Faraone, S.V., Marchant, B.K. et al. Gender differences in adults with ADHD, pretreatment and following treatment with atomoxetine under double-blind conditions. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.7.027.
200. Kostic, D., Oren, D., Marcus, R. et al. Intramuscular aripiprazole and lorazepam vs. placebo for agitation in acute mania. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.3.126.
201. Koran, L.M., Aboujaoude, E., Smith, E.H., Gamel, N. Escitalopram treatment of compulsive buying disorder: An open trial followed by double-blind discontinuation. Eur Neuropsychopharmacol 2005, 15(Suppl 3): Abst P.8.044.
202. Hall, J., Wohlreich, M., Mallinckrodt, C., Chappell, A., Myers, T., Raskin, J. Duloxetine for the treatment of major depressive disorder in elderly patients: Outcomes in patients with comorbid arthritis. Arthritis Rheum 2005, 52(9, Suppl): Abst 591.
203. Rosen, R., Shabsigh, R., Berber, M. et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: The depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006, 163(1): 79.
204. Phillips, K.A. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 2006, 21(3): 177.
205. Chico, G., Raza, A. Aripiprazole causes cholelithiasis and hepatitis: A rare finding. Am J Gastroenterol 2005, 100(9, Suppl): Abst 482.
206. Verma, A. et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005, 96(9): 1290.
207. Kaufmann, J.M., Dietrich, J.W. Safety and efficacy of avanafil, a new phosphodiesterase type-5(PDE-5) inhibitor for treating erectile dysfunction. J Urol 2006, 175(4, Suppl): Abst 923.
208. Valiquette, L. et al. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005, 80(10): 1291.
209. McClung, M., Siris, E., Cummings, S. et al. Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. J Bone Miner Res 2005, 20(Suppl 1): Abst F429.
210. Horvath, K., Walter, G., Varga, A., Romics, I. A novel approach to the treatment of benign prostatic hyperplasia. BJU Int 2006, 97(6): 1252.
211. Maykut, R., Massanari, M., Zeldin, R. et al. In moderate-severe asthma, omalizumab reduced the need for rescue systemic steroid bursts and improved ratings of treatment effectiveness: A pooled analysis. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 39.
212. Von Berg, A., Garcia, M.L., Hellbardt, S., Bethke, T.D. Ciclesonide 160 μg once daily is as effective as budesonide 400 μg once daily in pediatric patients with persistent asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 42.
213. Nayak, A., Herrera, O., Kundu, S., Lloyd, M., Banerji, D. Ciclesonide has no effect on growth in prepubertal children with mild, persistent asthma, irrespective of age and gender. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 738.
214. Maspero, J., Malka, S., Kundu, S., Lloyd, M., Banerji, D. Ciclesonide once daily is well tolerated in children with mild, persistent asthma: A 1-year, double-blind, placebo-controlled study. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 367.
215. Skoner, D., Maspero, J., Kundu, S., Lloyd, M., Banerji, D. Ciclesonide, administered once daily, has no effect on growth velocity in prepubertal children with mild, persistent asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 44.
216. Neffen, H., Ruff, M., Zhang, P., Lloyd, M., Banerji, D. Ciclesonide, administered once daily, has no effect on skeletal maturity in prepubertal children with mild, persistent asthma. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 714.
217. Ayre, G., Fox, H., Reisner, C. Evaluating response to omalizumab therapy in clinical practice. J Allergy Clin Immunol 2006, 117(2, Suppl 1):Abst 37.
218. Zeldin, R., Massanari, M., Maykut, R. et al. Omalizumab reduced need for steroid bursts in asthmatics concomitantly using leukotriene receptor antagonists (LTRAs). J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 1080.
219. Massanari, M., Kianifard, F., Maykut, R. et al. Omalizumab reduced need for steroid bursts and improved treatment effectiveness in asthmatics on inhaled salmeterol and fluticasone combination therapy. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 38.
220. Berger, W.E., Murray, J.J., Gross, G.N., Menendez, R., Walton-Bowen, K. Zileuton, 600 mg QID, provides early and sustained improvement in pulmonary function compared to placebo in moderate and severe asthmatic patients versus placebo. J Allergy Clin Immunol 2006, 117(2, Suppl 1): Abst 22.
221. van Noord, J.A., Aumann, J.L., Janssens, E. et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006, 129(3): 509.
222. Brashier, B., Jantikar, A., Maganji, M. et al. Addition of formoterol to tiotropium produces better FEVI and FVC responses when measured over 24 hours following single-dose administration in subjects with moderate-to-severe COPD. Chest 2005, 128(4, Suppl): 258S.
223. Gooding, J.A., Friedman, B., Markwalter, G., Mullins, R. The use of drotrecogin alfa (activated) in the treatment of chemical injury to the lungs. Crit Care Med 2005, 33(12, Suppl): Abst 285-M.
224. Schulze-Neick, I. et al. Adult patients with congenital heart disease and pulmonary arterial hypertension: First open prospective multicenter study of bosentan therapy. Am Heart J 2005, 150(4): 716.e7.
225. Rosenzweig, E.B. et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005, 46(4): 697.
226. Singh, S.D., Singh, M.K., Singh, N.B., Singh, R.K.B. Short-term results of tadalafil in severe pulmonary arterial hypertension. Indian Heart J 2005, 57(5): Abst 530.
227. Channick, R.N., Olschewski, H., Seeger, W., Staub, T., Rubin, L.J. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. Circulation 2005, 112(17, Suppl 2): Abst 2421.
228. Vachiery, J.-L., Pavelescu, A., Lang, I.M. et al. Subcutaneous treprostinil therapy in pulmonary arterial hypertension due to congenital heart diseases-A long term multicenter analysis. Circulation 2005, 112(17, Suppl 2): Abst 2043.
229. Tanghetti, E., Gold, M., Fraser, J. A two-center patient preference study comparing two benzoyl peroxide/clindamycin gels in acne vulgaris patients. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P01.141.
230. Myers, W. et al. Treatment of palmoplantar psoriasis with intramuscular alefacept. J Am Acad Dermatol 2005, 53(2, Part 2): S127.
231. Salavastru, C.M., Tiplica, O.S., Costache, M. Palmoplantar psoriasis treated with two-compound ointment containing calcipotriol and betamethasone dipropionate. J Eur Acad Dermatol Venereol 2005, 19(Suppl 2): Abst P06.6.
232. Papp, K.A., Miller, B., Gordon, K.B. et al. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 2006, 54(4, Suppl 1): S164.
233. Leonardi, C.L. et al. Extended efalizumab therapy improves chronic plaque psoriasis: Results from a randomized phase III trial. J Am Acad Dermatol 2005, 52(3): 425.
234. Gottlieb, A.B., Hamilton, T., Caro, I., Kwon, P., Compton, P.G., Leonardi, C.L. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: Updated results from an ongoing trial. J Am Acad Dermatol 2006, 54(4, Suppl 1): S154.
235. Commeau, P., Roquebert, P.-O., Barragan, P. Sirolimus for in-stent restenosis: Long term results of SiroJSR registry. Am J Cardiol 2005, 96(7, Suppl 1): Abst TCT-234.
236. Frilling, A., Stavrou, G.A., Mischinger, H.J. et al. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: A randomised prospective trial. Langenbeck's Arch Surg 2005, 390(2): 114.
237. Ibrahim, A., Mugharbil, A., Droubi, N. et al. Empirical therapy with caspofungin is safe and highly effective in patients at high risk of invasive or systemic fungal infections undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 2006, 37(Suppl 1): Abst P725.
238. Kirk, A.D. et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005, 80(8): 1051.
239. Mukhopadhyay, S., Sharma, M., Yusuf, J. et al. Phosphodiesterase-5 inhibitors in Eisenmenger syndrome: A new therapeutic option. Indian Heart J 2005, 57(5): Abst 535.
240. Schmitt-Hoffmann, A., Roos, B., Maares, J. et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006, 50(1): 286.
241. Shaddinger, B.C., Gao, L., Cai, G., Wentzell, L.M., Johnson, A.G. A study to evaluate the effect of repeat oral doses of SB-480848 on platelet function as compared to placebo in healthy subjects. Clin Pharmacol Ther 2006, 79(2): Abst PII-3.
242. Boy, S., Reitz, A., Simitovic, S., Knapp, P.A., Schurch, B. A facilitatory neuromodulative effect of duloxetine and pelvic floor training on the excitability of urethral sphincter motor neurons. Eur Urol Suppl 2006, 5(2): Abst 1112.
243. Barbosa, I.C., Filho, C.I., Faggion, D. Jr., Baracat, B.C. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 μg and ethinylestradiol 15 μg (Minesse(R)). Contraception 2006, 73(1): 30.
244. McConell, G.K. et al. L-Arginine infusion increases glucose clearance during prolonged exercise in humans. Am J Physiol Endocrinol Metab 2006, 290(1): E60.
245. Ghahramani, P., Hammett, T., Oliver, S. et al. The effect on cardiac repolarization after coadministration of single dose ZD6474 and ondansetron in healthy volunteers. Ann Oncol 2005, 16 (Suppl 2): Abst 140P.
246. Twiss, I.M., van den Berk, A.H., de Kam, M.L. et al. A comparison of the gastrointestinal effects of the nitrogen-containing bisphosphonates pamidronate, alendronate, and olpadronate in humans. J Clin Pharmacol 2006, 46(4): 483.
247. Cripps, A.W., Peek, K., Dunkley, M. et al. Safety and immunogenicity of an oral inactivated whole-cell pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun 2006, 74(2): 968.
248. Salinas, M. et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414. A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005, 24(9): 807.
249. Prince, W., Campbell, A.S., Tong, W. et al. SLx-2101, a new long-acting PDE5 inhibitor: Preliminary safety, tolerability, PK and endothelial function effects in healthy subjects. J Urol 2006, 175(4, Suppl): Abst 924.
250. Firbas, C., Jilma, B., Tauber, E. et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine 2006, 24(20): 4343.
251. Dowell, J.A. et al. Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 2005, 45(12): 1373.